Vaxcyte reposted this
Today we announced positive topline results from the Phase 1/2 study of VAX-31, our 31-valent pneumococcal conjugate vaccine (PCV) candidate, in healthy adults aged 50 and older. We are exceptionally proud to share these results, which we believe validate VAX-31’s potential as a best-in-class pneumococcal vaccine capable of raising the bar for immunogenicity standards. The public health community continues to highlight the need for broader-protection vaccines to prevent invasive pneumococcal disease, which is associated with high case-fatality rates, antibiotic resistance and meningitis. To address this need, VAX-31 was designed to increase coverage to more than 95% of IPD circulating in adults 50 and older in the United States, with the potential to provide significantly greater coverage relative to today’s standard-of-care adult PCVs. We want to extend a sincere thank you to everyone involved in this program, especially trial investigators, trial sites, study participants and the entire Vaxcyte team. For more, read the full press release here: https://lnkd.in/g72D5AUd #Vaccines #Biotechnology #ProtectHumankind #PCV